Contributions
Type: Publication Only
Background
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) play an important role in the initiation of angiogenesis.
Aims
We aimed to assess whether polymorphisms located within the genes coding for these key angiogenic activators (VEGF (rs3025039; C>T) and bFGF (rs308395, G>C)) contribute to disease susceptibility and/or progression in patients with multiple myeloma (MM) and response to chemotherapy.
Methods
For this purpose, 133 patients with MM and 122 healthy individuals were typed for the VEGF and bFGF alleles by PCR-RFLP technique.
Results
Patients and controls presented with similar distributions the VEGF and bFGF alleles and genotypes, thus none of the polymorphisms was associated with the risk of MM. However, it was observed that patients presented with stage I-II of the disease (according to the Durie-Salmon criteria) more frequently carried the bFGF-923G allele as compared to patients in stage III of MM (0.31 vs 0.16, p=0.052) and healthy controls (OR=2.010, p=0.040). Progression of the disease after first line chemotherapy was more frequent among patients carrying this allelic variant (6/32 vs 4/88, p=0.022).
Summary
Clinical course of disease in patients with multiple myeloma is associated with a polymorphism within the bFGF promoter region.
Keyword(s): FGF, Myeloma, Polymorphism
Session topic: Publication Only
Type: Publication Only
Background
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) play an important role in the initiation of angiogenesis.
Aims
We aimed to assess whether polymorphisms located within the genes coding for these key angiogenic activators (VEGF (rs3025039; C>T) and bFGF (rs308395, G>C)) contribute to disease susceptibility and/or progression in patients with multiple myeloma (MM) and response to chemotherapy.
Methods
For this purpose, 133 patients with MM and 122 healthy individuals were typed for the VEGF and bFGF alleles by PCR-RFLP technique.
Results
Patients and controls presented with similar distributions the VEGF and bFGF alleles and genotypes, thus none of the polymorphisms was associated with the risk of MM. However, it was observed that patients presented with stage I-II of the disease (according to the Durie-Salmon criteria) more frequently carried the bFGF-923G allele as compared to patients in stage III of MM (0.31 vs 0.16, p=0.052) and healthy controls (OR=2.010, p=0.040). Progression of the disease after first line chemotherapy was more frequent among patients carrying this allelic variant (6/32 vs 4/88, p=0.022).
Summary
Clinical course of disease in patients with multiple myeloma is associated with a polymorphism within the bFGF promoter region.
Keyword(s): FGF, Myeloma, Polymorphism
Session topic: Publication Only